Gland Pharma to Host Earnings Call for Q4 FY26 on May 15, 2026
Gland Pharma Ltd. has scheduled an earnings conference call to discuss its financial performance and business updates. The call is set for the fourth quarter of the financial year 2026 (Q4 FY26), covering the period ending March 31, 2026.The Earnings Conference Call for Q4 FY26 is scheduled for Friday, May 15, 2026, starting at 18:30 hours (IST). During the call, the management team will discuss the company's performance and answer questions related to the business.
The audio recording and transcript of the conference call will be made available on the company's website following the event.
The dial-in information for the event has been provided as follows:
| Access Type | Details |
|---|---|
| Universal Access | +91 22 6280 1516, +91 22 7115 8875 |
| International Toll-Free Number | USA: 18667462133, UK: 08081011573, Singapore: 8001012045, Hong Kong: 800964448 |
The company's management team will use this platform to review the business performance and address investor questions concerning the results for the quarter and financial year ended March 31, 2026.
GLAND Stock Price Movement
Shares of Gland Pharma Limited today slipped by 0.79% to settle at ₹1781, trailing its previous close. Trading activity saw the stock clear a volume of 110,104 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.